Synergism from combinations of tris (benzimidazole) monochloroplatinum(II) chloride with Capsaicin, Quercetin, Curcumin and Cisplatin in human ovarian cancer cell lines

Anticancer Research

Volumn 34, Issue 10, 2014, Pages 5453-5464

  Arzuman, Laila ^a   Beale, Philip ^b   Chan, Charles ^b   Yu, Jun Q ^a   Huq, Fazlul ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

Author keywords

Benzimidazole; Drug combination; Drug resistance; Monofunctional platinum; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CAPSAICIN; CISPLATIN; CURCUMIN; QUERCETIN; TRIS(BENZIMIDAZOLE) MONOCHLROROPLATINUM CHLORIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; DNA ADDUCT; PLATINUM COMPLEX;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER RESISTANCE; CYTOTOXICITY ASSAY; DNA BINDING; DNA FRAGMENTATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; INFRARED SPECTROSCOPY; OVARY CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; BIOLOGICAL MODEL; CELL SURVIVAL; CHEMISTRY; DNA ADDUCT; DOSE RESPONSE; DRUG EFFECTS; IC50; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CAPSAICIN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CURCUMIN; DNA ADDUCTS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; ORGANOPLATINUM COMPOUNDS; QUERCETIN;

EID: 84917733252     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Helm CW and States JC: Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. J Ovarian Res 2: 2-7, 2009.
2. Solomon LA, Ali S, Banerjee S, Munkarah AR, Morris RT and Sarkar FH: Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB. J Ovarian Res 1: 9, 2008.
3. Schuijer M and Berns EMJJ: TP53 and ovarian cancer. Hum Mutat 21: 285-291, 2003.
4. Chan MM and Fong D: Overcoming ovarian cancer drug resistance with phytochemicals and other compounds. Drug Resist Neoplasms pp. 187-216, 2009.
5. Chan MM and Fong D: Overcoming ovarian cancer drug resistance with phytochemicals and other compounds. Prog Cancer Drug Resist Res pp. 1-28, 2007.
6. Park GY, Wilson JJ, Song Y and Lippard SJ: Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci USA 109: 11987-11992, 2012.
7. Oyagbemi AA, Saba AB and Azeez OI: Capsaicin: a novel chemopreventive molecule and its underlying molecular mechanisms of action. Indian J Cancer 47: 53-58, 2010.
8. Jeon JH, Choi YJ, Han IH, Choi BK, Cha SH and Cho WH: Capsaicin-induced apoptosis in the human glioblastoma U87MG cells via p-38 MAPK and Bcl-2/Bax signaling pathway. Mol Cell Toxicol 8: 69-76, 2012.
9. Cordell GA and Araujo OE: Capsaicin: identification, nomenclature, and pharmacotherapy. Ann Pharmacother 27: 330-336, 1993.
10. Surh Y-J, Lee E and Lee JM: Chemoprotective properties of some pungent ingredients present in red pepper and ginger. Mutat Res, Fundam Mol Mech Mutagen 402: 259-267, 1998.
11. 2+ and caspase-3 in capsaicin-induced apoptosis of human leukemia HL-60 cells. Anticancer Res 26: 1965-1972, 2006.
12. Lo Y-C, Yang Y-C, Wu IC, Kuo F-C, Liu C-M, Wang H-W, Kuo C-H, Wu J-Y and Wu D-C: Capsaicin-induced cell death in a human gastric adenocarcinoma cell line. World J Gastroenterol 11: 6254-6257, 2005.
13. Surh YJ: Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res, Fundam Mol Mech Mutagen 428: 305-327, 1999.
14. Deorukhkar A, Krishnan S, Sethi G and Aggarwal BB: Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Invest Drugs 16: 1753-1773, 2007.
15. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung B, and Anand P: Potential of spice-derived phytochemicals for cancer prevention. Planta Med 74: 1560-1569, 2008.
16. Formica JV and Regelson W: Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 33: 1061-1080, 1995.
17. Vinod BS, Maliekal TT and Anto RJ: Phytochemicals As Chemosensitizers: From Molecular Mechanism to Clinical Significance. Antioxid Redox Signaling 18: 1307-1348, 2013.
18. Chan MM, Fong D, Soprano KJ, Holmes WF and Heverling H: Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 194: 63-70, 2003.
19. Jeong J-H, An JY, Kwon YT, Rhee JG and Lee YJ: Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression. J Cell Biochem 106: 73-82, 2008.
20. Lee Y-K, Hwang J-T, Kwon D-Y, Surh Y-J and Park O-J: Induction of apoptosis by quercetin is mediated through AMPKinnodataalpha1/ASK1/p38 pathway. Cancer Lett (Shannon, Irel) 292: 228-236, 2010.
21. Lugli E, Troiano L, Ferraresi R, Roat E, Prada N, Nasi M, Pinti M, Cooper EL and Cossarizza A: Characterization of cells with different mitochondrial membrane potential during apoptosis. Cytometry Part A 68A: 28-35, 2005.
22. HemaIswarya S and Doble M: Potential synergism of natural products in the treatment of cancer. Phytother Res 20: 239-249, 2006.
23. Reuter S, Eifes S, Dicato M, Aggarwal BB and Diederich M: Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 76: 1340-1351, 2008.
24. Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett (Shannon, Irel) 269: 199-225, 2008.
25. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman A-R, Kennedy R, Foster R, Mahoney J, Seiden MV and D'Andrea AD: Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 5: 952-961, 2006.
26. Shi M, Cai Q, Yao L, Mao Y, Ming Y and Ouyang G: Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int 30: 221-226, 2006.
27. Freshney RI: Culture of animal cells: a manual of basic technique. Newyork: Wiley-Less, 2000.
28. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
29. Chou T-C: Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 59: 253-276, 1976.
30. Di Blasi P, Bernareggi A, Beggiolin G, Piazzoni L, Menta E and Formento ML: Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinum complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells. Anticancer Res 18: 3113-3117, 1998.
31. Bowtell DDL: Rapid isolation of eukaryotic DNA. Anal Biochem 162: 463-465, 1987.
32. Mazumder MEH, Beale P, Chan C, Yu JQ and Huq F: Synthesis and Cytotoxicity of Three trans-Palladium Complexes Containing Planaramine Ligands in Human Ovarian Tumor Models. ChemMedChem 7: 1840-1846, 2012.
33. Kauffman GB and Cowan DO: cis-and trans-Dichlorodiammineplatinum( II). Inorg Syn 7: 239-245, 1963.
34. Dhara SC: A rapid method for the synthesis of cisplatin. Indian J Chem 8: 266-267, 1970.
35. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discovery 4: 307-320, 2005.
36. Tsuji A and Tamai I: Carrier-mediated intestinal transport of drugs. Pharm Res 13: 963-977, 1996.
37. Andrews PA, Velury S, Mann SC and Howell SB: cis- Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48: 68-73, 1988.
38. Lovejoy KS, Serova M, Bieche I, Emami S, D'Incalci M, Broggini M, Erba E, Gespach C, Cvitkovic E, Faivre S, Raymond E and Lippard SJ: Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells. Mol Cancer Ther 10: 1709-1719, 2011.
39. Sanchez AM, Sanchez MG, Malagarie-Cazenave S, Olea N and Diaz-Laviada I: Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin. Apoptosis 11: 89-99, 2006.
40. Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G and Aggarwal BB: Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin Cancer Res 13: 3024-3032, 2007.
41. Zhu G, Myint M, Ang WH, Song L and Lippard SJ: Monofunctional Platinum-DNA Adducts Are Strong Inhibitors of Transcription and Substrates for Nucleotide Excision Repair in Live Mammalian Cells. Cancer Res 72: 790-800, 2012.
42. Du G, Lin H, Wang M, Zhang S, Wu X, Lu L, Ji L and Yu L: Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in nodataalpha in tumor and normal cells. Cancer Chemother Pharmacol 65: 277-287, 2010.
43. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L and Pintzas A: Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 6: 2591-2599, 2007.
44. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN and Kirkwood JM: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745-2751, 1999.
45. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Porta VG, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Larriba JLG, Scherrer A and Menu Y: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 22: 1118-1125, 2004.
46. Thangasamy T, Sittadjody S, Limesand KH and Burd R: Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine. Cell Oncol 30: 371-387, 2008.
47. Thangasamy T, Sittadjody S, Mitchell Geoffrey C, Mendoza Erin E, Radhakrishnan Vijayababu M, Limesand Kirsten H, and Burd R: Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer 10: 282, 2010.
48. Chen C, Zhou J and Ji C: Quercetin: A potential drug to reverse multidrug resistance. Life Sci 87: 333-338, 2010.
49. Jakubowicz-Gil J, Paduch R, Piersiak T, Glowniak K, Gawron A and Kandefer-Szerszen M: The effect of quercetin on proapoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol 69: 1343-1350, 2005.
50. Kuhar M, Imran S and Singh N: Curcumin and quercetin combined with cisplatin to induce apoptosis in human laryngeal carcinoma Hep-2 cells through the mitochondrial pathway. J Cancer Mol 3: 121-128, 2007.
51. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC and D'Andrea AD: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9: 568-574, 2003.